Literature DB >> 26991896

Sickle-Cell Disease in Nigerian Children: Parental Knowledge and Laboratory Results.

Stephen K Obaro1, Yvonne Daniel, Juliana O Lawson, Wei-Wei Hsu, John Dada, Uduak Essen, Khalid Ibrahim, Adebayo Akindele, Kevin Brooks, Grace Olanipekun, Theresa Ajose, Claire E Stewart, Baba P D Inusa.   

Abstract

BACKGROUND: Sickle-cell disease (SCD) is the most common inherited genetic disorder in sub-Saharan Africa, and it is associated with early mortality and lifelong morbidity. Early diagnosis is essential for instituting appropriate care and preventive therapy.
OBJECTIVE: To compare parental knowledge or perception of their offspring's hemoglobin phenotype prior to testing and actual validated laboratory test results.
METHODS: In a prospective community-based survey, we assessed parental knowledge of their children's hemoglobin phenotype and corroborated this with the results from a laboratory confirmatory test determined by high-performance liquid chromatography.
RESULTS: We screened 10,126 children aged less than 5 years. A total of 163 (1.6%) parents indicated that their offspring had been previously tested and had knowledge of the child's hemoglobin genotype. However, 51 (31.2%) of 163 parents of children who had been previously tested did not know the result of their offspring's test, and 18 (35.3%) of these 51 children were found to have SCD. Of those who claimed previous knowledge, 25 (15.3%) of 163 reported incorrect results. Overall, we identified 272 (2.76%) new cases from 9,963 children who had not been previously tested.
CONCLUSION: There is the need to promote public awareness about SCD and the benefit of early diagnosis, quality assurance in laboratory diagnosis and institution of sustainable patient care pathways.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26991896     DOI: 10.1159/000444475

Source DB:  PubMed          Journal:  Public Health Genomics        ISSN: 1662-4246            Impact factor:   2.000


  2 in total

1.  Strategies to increase access to basic sickle cell disease care in low- and middle-income countries.

Authors:  Meghna Dua; Halima Bello-Manga; Yvonne M Carroll; Aisha Amal Galadanci; Umma Abdulsalam Ibrahim; Allison A King; Ayobami Olanrewaju; Jeremie H Estepp
Journal:  Expert Rev Hematol       Date:  2022-04-12       Impact factor: 2.819

2.  Feasibility and acceptability of early infant screening for sickle cell disease in Lagos, Nigeria-A pilot study.

Authors:  Esther O Oluwole; Titilope A Adeyemo; Gbemisola E Osanyin; Oluwakemi O Odukoya; Phyllis J Kanki; Bosede B Afolabi
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.